DASCOR received its CE Mark in Europe and was sold on a limited basis in Europe over the past three years. Unable to obtain FDA approval to commence a pivotal study in the U.S., it seems DD has exhausted all possible funding and with its operating funds depleted, DD commenced a wind down of its business effective December 31st, 2009 and has terminated all of its employees and discontinued all financial support of clinical studies.
$65 million? Hopefully, some of those prudent investors will have learned their lesson. IST, Archus, Vertebron, Inion, Pegasus, and now Disc Dynamics.
"lookin' back over the years, we've all shed some tears
Told ourselves time and time again, this time we're gonna win
But another fight, things ain't right, we're losin' again
Takes a fool to lose twice, and start over again
Think I better let it go, looks like another spine TKO
$65 million? No wonder the CEO left when he had the opportunity. How many more crazy ideas will we see where investors will throw millions of dollars at companies that are run by people that do not posess the skills nor business acumen to bring a venture to fruition? TSB wants to know what our readers have heard and what they think the residual fallout will be for many of the companies that are underfunded?